Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600X |
Therapy | Cobimetinib + Vemurafenib |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600X | lung non-small cell carcinoma | predicted - sensitive | Cobimetinib + Vemurafenib | Phase II | Actionable | In a Phase II trial, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an objective response rate (ORR) of 50% (18/36), median progression-free survival of 7.9 months, and overall survival of 15.9 months in patients with advanced solid tumors harboring a BRAF V600 mutation and an ORR of 42% (10/24) in treatment-naive patients with non-small cell lung cancer harboring a BRAF V600 mutation (Ann Oncol (2024) 35 (Suppl_2): S498). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12 | Full reference... |